Teva (TEVA) Enters a New $700 Million Acquisition Deal

Summary

On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced entering into a definitive agreement to acquire Emalex Biosciences.

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Related coverage